MagVenture announced today that it launched the patent-pending MagVenture Flow Arm for brain stimulation positioning.
Alpharetta, Ga.-based MagVenture’s Flow Arm clinical positioning system is designed to optimize the delivery of the company’s FDA-cleared protocols for non-invasive brain stimulation technology in treating major depressive disorder and as an adjunct therapy for OCD, according to a news release.
The MagVenture Flow Arm is touted by the company as the latest improvement to its MagVenture TMS (transcranial magnetic stimulation) Therapy system. It improves upon the applicator “coil,” which is usually large and unwieldy, the company said.
MagVenture said the coil is essentially comprised of two heavy spools of copper wire that produce and focus magnetic fields for the brain stimulation. The coil has to be accurately positioned and held immobile over the brain targets during TMS procedures.
However, MagVenture’s Flow Arm solution improves the ease of use for operators to almost effortlessly move and securely position TMS coils for non-invasive brain stimulation procedures.
“Responsiveness to customer needs is a core part of MagVenture DNA,” MagVenture SVP of sales Kerry Rome said in the release. “Throughout the R&D and testing phases for the Flow Arm project, the MagVenture organization here in the US has been waiting with much anticipation and, finally, we are super excited about the introduction of MagVenture’s patent-pending ‘Flow Arm’ for TMS coil positioning. It’s a game-changer for TMS providers seeking optimal ease of use and efficiency in their clinical TMS services and, in context with the current COVID-19 pandemic, the improvements in the MagVenture reduced treatment/operator-patient interaction time is going to prove to be a big positive.”